Last updated on August 2016

A randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate the effect of secukinumab on aortic vascular inflammation and cardiometabolic biomarkers after 12 weeks of treatment, compared to placebo, and up to 52 weeks of treatment with secukinumab in adult subjects with moderate to severe chronic plaque-type psoriasis


Brief description of study

A randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate the effect of secukinumab on aortic vascular inflammation and cardiometabolic biomarkers after 12 weeks of treatment, compared to placebo, and up to 52 weeks of treatment with secukinumab in adult subjects with moderate to severe chronic plaque-type psoriasis

Detailed Study Description

We are studying an injectable medication, secukinumab, in the treatment of moderate to severe plaque psoriasis. Patients will undergo 3 FDG-PET/CT scans during the study to assess inflammation of the large vessels in the body and the effects of secukinumab on this inflammation. The trial lasts for 52 weeks. Initially patients will be expected to attend weekly appointments. After the first month, the appointments will occur every one to two months. Patients must be able to inject the medications themselves or have a family member or friend inject the medication for them.

Clinical Study Identifier: TX10459

.

Contact Investigators or Research Sites near you

Start Over

Please choose location

View all locations

Bridget Kaufman

Mount Sinai St. Luke's
New York, NY USA
  Connect »